{"classes":[{"categories":[{"measurements":[{"comment":"The median time to complete resolution could not be estimated because \\<50% of patients had a complete resolution during the time period.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The median time to complete resolution could not be estimated because \\<50% of patients had a complete resolution during the time period.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"115"}],"units":"Participants"}],"description":"Patients scored their pain intensity on a 5-point Likert scale (none, mild, moderate, severe, extreme). Complete Resolution of Pain is defined as no pain (None) on the Likert Scale. Pain was scored at Baseline; at 6 and 12 hours post-dose; and at 1, 2, 3, 4, 5, 6, and 7 days post-dose. The Kaplan-Meier estimates of time to complete resolution of self-assessed pain intensity in the joint most affected and their confidence intervals were determined.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients received 1 subcutaneous (sc) injection of canakinumab 150 mg and 1 intramuscular (im) injection of placebo to triamcinolone acetonide on Day 1. Patients could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Patients completing the 12 weeks core study were allowed to continue to be treated in another 12 weeks extension study for any new gout flare on demand with the same treatment as assigned in the core study.","id":"OG000","title":"Canakinumab 150 mg"},{"description":"Patients received 1 intramuscular (im) injection of triamcinolone acetonide 40 mg and 1 subcutaneous (sc) injection of placebo to canakinumab on Day 1. Patients could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Patients completing the 12 weeks core study were allowed to continue to be treated in another 12 weeks extension study for any new gout flare on demand with the same treatment as assigned in the core study.","id":"OG001","title":"Triamcinolone Acetonide 40 mg"}],"paramType":"MEDIAN","populationDescription":"The Full Analysis Set (FAS) consisted of all patients as randomized in the core study who had taken at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"7 days post-dose (randomization)","title":"Time to Complete Resolution of Pain","type":"SECONDARY","unitOfMeasure":"Hours"}